Among patients with mechanical heart valves receiving warfarin anticoagulation, in-home does not differ from in-clinic monitoring of international normalized ratio in terms of therapeutic range and important clinical outcomes, according to real-world data.
Suppressing neutrophil serine protease activity with brensocatib appears to benefit patients with bronchiectasis, yielding improvements in clinical outcomes, according to the results of a phase II study.
Use of canagliflozin leads to a decrease in amino-terminal pro–B-type natriuretic peptide (NT-proBNP) concentrations as compared with placebo, but the reduction in NT-proBNP explains only a small part of the benefit of this agent on heart failure (HF) events, suggests a recent study.
Patients with chronic lymphocytic leukaemia are better off with acalabrutinib than other therapies, with the drug ranking highest in treatment efficacy according to the results of a network meta-analysis.
Digoxin initiation prior to hospital discharge does not appear to contribute to 30-day or 6-year outcomes in older hospitalized patients with heart failure with preserved ejection fraction (HFpEF), results of a recent study have shown.
Thiopurine appears beneficial for long-term treatment of patients with ulcerative colitis (UC) but not for those with Crohn’s disease (CD) especially where there is perianal involvement, a study has found.
No baseline clinical factor is predictive of treatment success in women receiving medical management with misoprostol for early pregnancy loss, according to a study. However, the addition of mifepristone seems to improve treatment success.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.